NIHR-supported trial tests a rapid, low-cost point-of-care test that can diagnose flu, COVID‑19, and RSV in minutes, potentially speeding up winter diagnosis and care across the NHS.
Josep Figueras and Anna Sagan from the European Observatory on Health Systems and Policies focus here on antimicrobial resistance and ponder whether or not this could be the next big pandemic.
Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.
Professor Tilmann Weber discusses how microbial genomics helps to find the next generation of antibiotics in the race against antimicrobial resistance.
Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
